Table 1. Performance of Dectin-coated AmB-loaded liposomes targeted to fungal cells, relative to untargeted AmB-LLs.
| A. In vitro assays | ||||||
| DectiSomes | Pathogen (disease) | Increase in liposome bindinga | Increase in killing/growth inhibitiona | |||
| DEC1-AmB-LLs | A. fumigatus (aspergillosis) | >200-fold | 5- to 50-fold | |||
| C. albicans (candidiasis) | Yesb | N.D.c | ||||
| C. neoformans (cryptococcosis) | Yesb | N.D.c | ||||
| DEC2-AmB-LLs | A. fumigatus (aspergillosis) | >50-fold | >30-fold | |||
| C. albicans (candidiasis) | >100-fold | Approximately 90-fold | ||||
| C. neoformans (cryptococcosis) | >100-fold | Approximately 10-fold | ||||
| B. In vivo assays in murine models of pulmonary aspergillosis | ||||||
| DEC2-AmB-LLs | Increase in liposome binding in lungsa | Reduction in fungal burden in the lungsa | Increase in days of survival vs AmB-LLsd | Increase in percent of surviving miced | ||
| Neutropenic model | 30-fold | 12- to 42-fold | 3.5 to 18.4 days | 8% to 58% | ||
| Steroid model | N.D.c | 8- to 22-fold | N.D.c | N.D.c | ||
aRelative to untargeted AmB-LL delivering the same AmB concentration.
bQualitative observation.
cN.D., not done.
dSurvival study terminated 24 days after infection.